Pharsight

1. List of Bonjesta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089489	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)
US9526703	DUCHESNAY	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)
US9375404	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)
US9937132	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)

Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 November, 2016

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg/20 mg	28 Aug, 2018	1	01 Mar, 2022	18 Feb, 2033	Deferred

Strength	Dosage	Availability
20MG;20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

2. List of Osphena drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566252	DUCHESNAY	Method for the alleviation of dyspareunia in women	Nov, 2022 (3 months ago)
US8772353	DUCHESNAY	Method for enhancing the bioavalability of ospemifene	Feb, 2024 (1 year, 9 days from now)
US9241915	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 9 days from now)
US9855224	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 9 days from now)
US8470890	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 9 days from now)
US6245819	DUCHESNAY	Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause	Jul, 2025 (2 years from now)
US8236861	DUCHESNAY	Method for enhancing the bioavailablity of ospemifene	Aug, 2026 (3 years from now)
US8642079	DUCHESNAY	Solid formulations of ospemifene	Jul, 2028 (5 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Jan 25, 2022

Drugs and Companies using OSPEMIFENE ingredient

Market Authorisation Date: 26 February, 2013

Treatment: Treatment of dyspareunia associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene

Dosage: TABLET;ORAL